# Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM

Source: https://onco.cc/trials/nct06630624/  
OnCo record `nct06630624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in colorectal cancer, run by M.R. Meijerink, now recruiting.

## Summary

Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM is a phase 1/2, interventional study registered as NCT06630624 by M.R. Meijerink, with a registry enrolment figure of 120 participants, started 2024-07-10 and due to reach its primary completion in 2029-08-01. Interventions recorded: IP-001. Conditions listed: Colorectal Cancer; Liver Metastases; Liver Metastasis Colon Cancer. Primary outcome: Maximum Tolerated Dose (MTD) (Phase 1); 1-Year Distant Progression Free Survival (DPFS) (Phase 2 part 1); Disease Control Rate (DCR) (Phase 2 part 2). Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: INJECTABL-II
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06630624
- Phase: 1/2
- Setting: INJECTABL-II: Dose Finding, Efficacy and Immunological Response of a Novel Immuno-Adjuvant (IP-001) Following Microwave Ablation or Irreversible Electroporation for Colorectal Liver Metastases.
- Sponsor: M.R. Meijerink
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06630624: https://clinicaltrials.gov/study/NCT06630624

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Thermal ablation (RFA, microwave, cryo)](https://onco.cc/technologies/thermal-ablation/)
- companies: [AngioDynamics](https://onco.cc/companies/angiodynamics/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06630624.json